Skip to main content

Advertisement

SpringerLink
Log in

Effect of Intrastriatal 6-OHDA Lesions on Extrastriatal Brain Structures in the Mouse

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by progressive loss of midbrain dopaminergic neurons, resulting in motor and non-motor symptoms. The underlying pathology of non-motor symptoms is poorly understood. Discussed are pathological changes of extrastriatal brain structures. In this study, we characterized histopathological alterations of extrastriatal brain structures in the 6-hydroxydopamine (6-OHDA) PD animal model. Lesions were induced by unilateral stereotactic injections of 6-OHDA into the striatum or medial forebrain bundle of adult male mice. Loss of tyrosine hydroxylase positive (TH+) fibers as well as glia activation was quantified following stereological principles. Loss of dopaminergic innervation was further investigated by western-blotting. As expected, 6-OHDA injection into the nigrostriatal route induced retrograde degeneration of dopaminergic neurons within the substantia nigra pars compacta (SNpc), less so within the ventral tegmental area. Furthermore, we observed a region-specific drop of TH+ projection fiber density in distinct cortical regions. This pathology was most pronounced in the cingulate- and motor cortex, whereas the piriform cortex was just modestly affected. Loss of cortical TH+ fibers was not paralleled by microglia or astrocyte activation. Our results demonstrate that the loss of dopaminergic neurons within the substantia nigra pars compacta is paralleled by a cortical dopaminergic denervation in the 6-OHDA model. This model serves as a valuable tool to investigate mechanisms operant during cortical pathology in PD patients. Further studies are needed to understand why cortical dopaminergic innervation is lost in this model, and what functional consequence is associated with the observed denervation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. World Health Organization W (2006) Neurological disorders: public health challenges. World Health Organization

  2. Farrer MJ (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 7(4):306–318. doi:10.1038/nrg1831

    Article  CAS  PubMed  Google Scholar 

  3. Chaudhuri KR, Schapira AHV (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464–474. doi:10.1016/S1474-4422(09)70068-7

    Article  CAS  PubMed  Google Scholar 

  4. Bezard E, Yue Z, Kirik D, Spillantini MG (2013) Animal models of Parkinson’s disease: limits and relevance to neuroprotection studies. Mov Disord 28(1):61–70. doi:10.1002/mds.25108

    Article  CAS  PubMed  Google Scholar 

  5. Blandini F, Levandis G, Bazzini E, Nappi G, Armentero M-T (2007) Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur J Neurosci 25(2):397–405. doi:10.1111/j.1460-9568.2006.05285.x

    Article  PubMed  Google Scholar 

  6. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67(3):631–647

    Article  CAS  PubMed  Google Scholar 

  7. Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59(2):401–415. doi:10.1016/0306-4522(94)90605-X

    Article  CAS  PubMed  Google Scholar 

  8. Stott SR, Barker RA (2014) Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson’s disease. Eur J Neurosci 39(6):1042–1056. doi:10.1111/ejn.12459

    Article  PubMed  Google Scholar 

  9. Gravotta L, Gavrila AM, Hood S, Amir S (2011) Global depletion of dopamine using intracerebroventricular 6-hydroxydopamine injection disrupts normal circadian wheel-running patterns and PERIOD2 expression in the rat forebrain. J Mol Neurosci 45(2):162–171. doi:10.1007/s12031-011-9520-8

    Article  CAS  PubMed  Google Scholar 

  10. Requejo C, Ruiz-Ortega JA, Bengoetxea H, Garcia-Blanco A, Herran E, Aristieta A, Igartua M, Pedraz JL et al (2016) Morphological changes in a severe model of Parkinson’s disease and its suitability to test the therapeutic effects of microencapsulated neurotrophic factors. Mol Neurobiol. doi:10.1007/s12035-016-0244-1

  11. Berger B, Tassin JP, Blanc G, Moyne MA, Thierry AM (1974) Histochemical confirmation for dopaminergic innervation of the rat cerebral cortex after destruction of the noradrenergic ascending pathways. Brain Res 81(2):332–337. doi:10.1016/0006-8993(74)90948-2

    Article  CAS  PubMed  Google Scholar 

  12. Fallon JH, Moore RY (1978) Catecholamine innervation of the basal forebrain. III. Olfactory bulb, anterior olfactory nuclei, olfactory tubercle and piriform cortex. J Comp Neurol 180(3):533–544. doi:10.1002/cne.901800309

    Article  CAS  PubMed  Google Scholar 

  13. Gaspar P, Berger B, Febvret A, Vigny A, Henry JP (1989) Catecholamine innervation of the human cerebral cortex as revealed by comparative immunohistochemistry of tyrosine hydroxylase and dopamine-beta-hydroxylase. J Comp Neurol 279(2):249–271. doi:10.1002/cne.902790208

    Article  CAS  PubMed  Google Scholar 

  14. Verney C, Baulac M, Berger B, Alvarez C, Vigny A, Helle KB (1985) Morphological evidence for a dopaminergic terminal field in the hippocampal formation of young and adult rat. Neuroscience 14(4):1039–1052. doi:10.1016/0306-4522(85)90275-1

    Article  CAS  PubMed  Google Scholar 

  15. Baulac M, Verney C, Berger B (1986) Dopaminergic innervation of the parahippocampal and hippocampal regions in the rat. Rev Neurol 142(12):895–905

    CAS  PubMed  Google Scholar 

  16. Gasbarri A, Verney C, Innocenzi R, Campana E, Pacitti C (1994) Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: a combined retrograde tracing and immunohistochemical study. Brain Res 668(1–2):71–79. doi:10.1016/0006-8993(94)90512-6

    Article  PubMed  Google Scholar 

  17. Goldsmith SK, Joyce JN (1994) Dopamine D2 receptor expression in hippocampus and parahippocampal cortex of rat, cat, and human in relation to tyrosine hydroxylase-immunoreactive fibers. Hippocampus 4(3):354–373. doi:10.1002/hipo.450040318

    Article  CAS  PubMed  Google Scholar 

  18. Kalia M, Fuxe K, Goldstein M (1985) Rat medulla oblongata. II. Dopaminergic, noradrenergic (A1 and A2) and adrenergic neurons, nerve fibers, and presumptive terminal processes. J Comp Neurol 233(3):308–332. doi:10.1002/cne.902330303

    Article  CAS  PubMed  Google Scholar 

  19. Gaspar P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B (1991) Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson’s disease. Ann Neurol 30(3):365–374. doi:10.1002/ana.410300308

    Article  CAS  PubMed  Google Scholar 

  20. Tzschentke TM (2001) Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 63(3):241–320

    Article  CAS  PubMed  Google Scholar 

  21. Paxinos G, Franklin KBJ (2001) Mouse brain in stereotaxic coordinates, 2nd edn. Academic, San Diego

  22. Slowik A, Schmidt T, Beyer C, Amor S, Clarner T, Kipp M (2015) The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination. Br J Pharmacol 172(1):80–92. doi:10.1111/bph.12938

    Article  CAS  PubMed  Google Scholar 

  23. Dunnett SB, Iversen SD (1982) Spontaneous and drug-induced rotation following localized 6-hydroxydopamine and kainic acid-induced lesions of the neostriatum. Neuropharmacology 21(9):899–908

    Article  CAS  PubMed  Google Scholar 

  24. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24(3):485–493

    Article  CAS  PubMed  Google Scholar 

  25. Wagenknecht N, Becker B, Scheld M, Beyer C, Clarner T, Hochstrasser T, Kipp M (2016) Thalamus degeneration and inflammation in two distinct multiple sclerosis animal models. J Mol Neurosci 60(1):102–114. doi:10.1007/s12031-016-0790-z

    Article  CAS  PubMed  Google Scholar 

  26. Grosse-Veldmann R, Becker B, Amor S, van der Valk P, Beyer C, Kipp M (2016) Lesion expansion in experimental demyelination animal models and multiple sclerosis lesions. Mol Neurobiol 53(7):4905–4917. doi:10.1007/s12035-015-9420-y

    Article  CAS  PubMed  Google Scholar 

  27. Hochstrasser T, Exner GL, Nyamoya S, Schmitz C, Kipp M (2017) Cuprizone-containing pellets are less potent to induce consistent demyelination in the corpus callosum of C57BL/6 mice. J Mol Neurosci 61(4):617–624. doi:10.1007/s12031-017-0903-3

    Article  CAS  PubMed  Google Scholar 

  28. Goldberg J, Clarner T, Beyer C, Kipp M (2015) Anatomical distribution of cuprizone-induced lesions in C57BL6 mice. J Mol Neurosci 57(2):166–175. doi:10.1007/s12031-015-0595-5

    Article  CAS  PubMed  Google Scholar 

  29. Mangano EN, Peters S, Litteljohn D, So R, Bethune C, Bobyn J, Clarke M, Hayley S (2011) Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson’s disease. Neurobiol Dis 43(1):99–112. doi:10.1016/j.nbd.2011.02.011

    Article  CAS  PubMed  Google Scholar 

  30. Li HP, Komuta Y, Kimura-Kuroda J, van Kuppevelt TH, Kawano H (2013) Roles of chondroitin sulfate and dermatan sulfate in the formation of a lesion scar and axonal regeneration after traumatic injury of the mouse brain. J Neurotrauma 30(5):413–425. doi:10.1089/neu.2012.2513

    Article  PubMed  PubMed Central  Google Scholar 

  31. Heppner FL, Roth K, Nitsch R, Hailer NP (1998) Vitamin E induces ramification and downregulation of adhesion molecules in cultured microglial cells. Glia 22(2):180–188

    Article  CAS  PubMed  Google Scholar 

  32. Eder C, Schilling T, Heinemann U, Haas D, Hailer N, Nitsch R (1999) Morphological, immunophenotypical and electrophysiological properties of resting microglia in vitro. Eur J Neurosci 11(12):4251–4261

    Article  CAS  PubMed  Google Scholar 

  33. Häggendal J, Hamberger B (1967) Quantitative in vitro studies on noradrenaline uptake and its inhibition by amphetamine, desipramine and chlorpromazine. Acta Physiol Scand 70(3–4):277–280. doi:10.1111/j.1748-1716.1967.tb03626.x

    Article  PubMed  Google Scholar 

  34. Ross SB, Renyi AL (1967) Inhibition of the uptake of tritiated catecholamines by antidepressant and related agents. Eur J Pharmacol 2(3):181–186

    Article  CAS  PubMed  Google Scholar 

  35. Hudson JL, van Horne CG, Strömberg I, Brock S, Clayton J, Masserano J, Hoffer BJ, Gerhardt GA (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626(1–2):167–174

    Article  CAS  PubMed  Google Scholar 

  36. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24(3):485–493. doi:10.1016/0006-8993(70)90187-3

    Article  CAS  PubMed  Google Scholar 

  37. Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, Oertel WH, Hartmann A (2008) Characterization of the striatal 6-OHDA model of Parkinson’s disease in wild type and α-synuclein-deleted mice. Exp Neurol 210(1):182–193. doi:10.1016/j.Expneurol.2007.10.012

    Article  CAS  PubMed  Google Scholar 

  38. Deutch AY, Goldstein M, Baldino F Jr, Roth RH (1988) Telencephalic projections of the A8 dopamine cell group. Ann N Y Acad Sci 537:27–50

    Article  CAS  PubMed  Google Scholar 

  39. Vollbrecht PJ, Simmler LD, Blakely RD, Deutch AY (2014) Dopamine denervation of the prefrontal cortex increases expression of the astrocytic glutamate transporter GLT-1. J Neurochem 130(1):109–114. doi:10.1111/jnc.12697

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kipp M, Kiessling MC, Hochstrasser T, Roggenkamp C, Schmitz C (2017) Design-based stereology for evaluation of histological parameters. J Mol Neurosci 61(3):325–342. doi:10.1007/s12031-016-0858-9

    Article  CAS  PubMed  Google Scholar 

  41. Block ML, Hong J-S (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76(2):77–98. doi:10.1016/j.pneurobio.2005.06.004

    Article  CAS  PubMed  Google Scholar 

  42. Streit WJ (1996) The role of microglia in brain injury. Neurotoxicology 17(3–4):671–678

    CAS  PubMed  Google Scholar 

  43. Dutra MF, Jaeger M, Ilha J, Kalil-Gaspar PI, Marcuzzo S, Achaval M (2012) Exercise improves motor deficits and alters striatal GFAP expression in a 6-OHDA-induced rat model of Parkinson’s disease. Neurol Sci 33(5):1137–1144. doi:10.1007/s10072-011-0925-5

    Article  PubMed  Google Scholar 

  44. Anastasia A, Torre L, de Erausquin GA, Masco DH (2009) Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson’s disease. J Neurochem 109(3):755–765. doi:10.1111/j.1471-4159.2009.06001.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Henning J, Strauss U, Wree A, Gimsa J, Rolfs A, Benecke R, Gimsa U (2008) Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease. Neurosci Res 62(4):246–253. doi:10.1016/j.neures.2008.09.001

    Article  CAS  PubMed  Google Scholar 

  46. Chaudhuri KR, Healy DG, Schapira AHV (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5(3):235–245. doi:10.1016/S1474-4422(06)70373-8

    Article  PubMed  Google Scholar 

  47. Chaudhuri KR, Sauerbier A (2015) Parkinson disease: unravelling the nonmotor mysteries of Parkinson disease. Nat Rev Neurol 12(1):10–11. doi:10.1038/nrneurol.2015.236

    Article  Google Scholar 

  48. Hely MA, Morris JGL, Reid WGJ, Trafficante R (2005) Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord: Off J Mov Disord Soc 20(2):190–199. doi:10.1002/mds.20324

    Article  Google Scholar 

  49. Christopher L, Duff-Canning S, Koshimori Y, Segura B, Boileau I, Chen R, Lang AE, Houle S et al (2015) Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. Ann Neurol 77(2):269–280. doi:10.1002/ana.24323

    Article  CAS  PubMed  Google Scholar 

  50. Christopher L, Marras C, Duff-Canning S, Koshimori Y, Chen R, Boileau I, Segura B, Monchi O et al (2014) Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson’s disease with mild cognitive impairment. Brain 137(Pt 2):565–575. doi:10.1093/brain/awt337

    Article  PubMed  Google Scholar 

  51. Apitz T, Bunzeck N (2013) Dopamine controls the neural dynamics of memory signals and retrieval accuracy. Neuropsychopharmacology 38(12):2409–2417. doi:10.1038/npp.2013.141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Alexander GE (2004) Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci 6(3):259–280

    PubMed  PubMed Central  Google Scholar 

  53. Blandini F, Armentero MT (2012) Animal models of Parkinson’s disease. FEBS J 279(7):1156–1166. doi:10.1111/j.1742-4658.2012.08491.x

    Article  CAS  PubMed  Google Scholar 

  54. Bove J, Perier C (2012) Neurotoxin-based models of Parkinson’s disease. Neuroscience 211:51–76. doi:10.1016/j.neuroscience.2011.10.057

    Article  CAS  PubMed  Google Scholar 

  55. Ungerstedt U (1968) 6-hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5(1):107–110. doi:10.1016/0014-2999(68)90164-7

    Article  CAS  PubMed  Google Scholar 

  56. Berger K, Przedborski S, Cadet JL (1991) Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res Bull 26(2):301–307. doi:10.1016/0361-9230(91)90242-C

    Article  CAS  PubMed  Google Scholar 

  57. Tatenhorst L, Tonges L, Saal KA, Koch JC, Szego EM, Bahr M, Lingor P (2014) Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease. J Neuropathol Exp Neurol 73(8):770–779. doi:10.1097/nen.0000000000000095

    Article  CAS  PubMed  Google Scholar 

  58. He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909(1–2):187–193

    Article  CAS  PubMed  Google Scholar 

  59. Spieles-Engemann AL, Behbehani MM, Collier TJ, Wohlgenant SL, Steece-Collier K, Paumier K, Daley BF, Gombash S et al (2010) Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. Neurobiol Dis 39(1):105–115. doi:10.1016/j.nbd.2010.03.009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Luft AR, Schwarz S (2009) Dopaminergic signals in primary motor cortex. Int J Dev Neurosci 27(5):415–421. doi:10.1016/j.ijdevneu.2009.05.004

    Article  CAS  PubMed  Google Scholar 

  61. Moore RY, Whone AL, Brooks DJ (2008) Extrastriatal monoamine neuron function in Parkinson’s disease: an 18F-dopa PET study. Neurobiol Dis 29(3):381–390. doi:10.1016/j.nbd.2007.09.004

    Article  CAS  PubMed  Google Scholar 

  62. Fukuda T, Takahashi J, Tanaka J (1999) Tyrosine hydroxylase-immunoreactive neurons are decreased in number in the cerebral cortex of Parkinson’s disease. Neuropathology 19(1):10–13. doi:10.1046/j.1440-1789.1999.00196.x

    Article  CAS  PubMed  Google Scholar 

  63. Haas SJ, Zhou X, Machado V, Wree A, Krieglstein K, Spittau B (2016) Expression of Tgfbeta1 and inflammatory markers in the 6-hydroxydopamine mouse model of Parkinson’s disease. Front Mol Neurosci 9:7. doi:10.3389/fnmol.2016.00007

    Article  PubMed  PubMed Central  Google Scholar 

  64. Fan XT, Zhao F, Ai Y, Andersen A, Hardy P, Ling F, Gerhardt GA, Zhang Z et al (2014) Cortical glutamate levels decrease in a non-human primate model of dopamine deficiency. Brain Res 1552:34–40. doi:10.1016/j.brainres.2013.12.035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Jan C, Pessiglione M, Tremblay L, Tande D, Hirsch EC, Francois C (2003) Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys. Eur J Neurosci 18(7):2082–2086

    Article  PubMed  Google Scholar 

  66. Halje P, Tamtè M, Richter U, Mohammed M, Cenci MA, Petersson P (2012) Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. J Neurosci: Off J Soc Neurosci 32(47):16541–16551. doi:10.1523/JNEUROSCI.3047-12.2012

    Article  CAS  Google Scholar 

  67. Debeir T, Ginestet L, François C, Laurens S, Martel J-C, Chopin P, Marien M, Colpaert F et al (2005) Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus. Exp Neurol 193(2):444–454. doi:10.1016/j.expneurol.2005.01.007

    Article  CAS  PubMed  Google Scholar 

  68. Lindenbach D, Conti MM, Ostock CY, Dupre KB, Bishop C (2015) Alterations in primary motor cortex neurotransmission and gene expression in hemi-Parkinsonian rats with drug-induced dyskinesia. Neuroscience. doi:10.1016/j.neuroscience.2015.09.018

  69. Guo L, Xiong H, Kim J-I, Wu Y-W, Lalchandani RR, Cui Y, Shu Y, Xu T et al (2015) Dynamic rewiring of neural circuits in the motor cortex in mouse models of Parkinson’s disease. Nat Neurosci 18(9):1299–1309. doi:10.1038/nn.4082 http://www.nature.com/neuro/journal/v18/n9/abs/nn.4082.html#supplementary-information

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Deutch AY, Goldstein M, Baldino F, Roth RH (1988) Telencephalic projections of the A8 dopamine cell group. Ann N Y Acad Sci 537:27–50

    Article  CAS  PubMed  Google Scholar 

  71. Clarner T, Janssen K, Nellessen L, Stangel M, Skripuletz T, Krauspe B, Hess FM, Denecke B et al (2015) CXCL10 triggers early microglial activation in the cuprizone model. J Immunol 194(7):3400–3413. doi:10.4049/jimmunol.1401459

    Article  CAS  PubMed  Google Scholar 

  72. Clarner T, Diederichs F, Berger K, Denecke B, Gan L, van der Valk P, Beyer C, Amor S et al (2012) Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions. Glia 60(10):1468–1480. doi:10.1002/glia.22367

    Article  PubMed  Google Scholar 

  73. Gervasi NM, Scott SS, Aschrafi A, Gale J, Vohra SN, MacGibeny MA, Kar AN, Gioio AE et al (2016) The local expression and trafficking of tyrosine hydroxylase mRNA in the axons of sympathetic neurons. RNA (New York, NY) 22(6):883–895. doi:10.1261/rna.053272.115

    Article  CAS  Google Scholar 

  74. Godena VK, Brookes-Hocking N, Moller A, Shaw G, Oswald M, Sancho RM, Miller CC, Whitworth AJ et al (2014) Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat Commun 5:5245. doi:10.1038/ncomms6245

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Volpicelli-Daley LA, Gamble KL, Schultheiss CE, Riddle DM, West AB, Lee VM (2014) Formation of alpha-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. Mol Biol Cell 25(25):4010–4023. doi:10.1091/mbc.E14-02-0741

    Article  PubMed  PubMed Central  Google Scholar 

  76. Lamberts JT, Hildebrandt EN, Brundin P (2015) Spreading of alpha-synuclein in the face of axonal transport deficits in Parkinson’s disease: a speculative synthesis. Neurobiol Dis 77:276–283. doi:10.1016/j.nbd.2014.07.002

    Article  CAS  PubMed  Google Scholar 

  77. McDowell K, Chesselet MF (2012) Animal models of the non-motor features of Parkinson’s disease. Neurobiol Dis 46(3):597–606. doi:10.1016/j.nbd.2011.12.040

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by IZKF grants from the Faculty of Medicine (MK and ST). We thank Petra Ibold and Helga Helten for their valuable technical assistance.

Author information

Author notes

  1. Sonny Kian Hwie Tan and Markus Kipp contributed equally to this work.

Authors and Affiliations

  1. Institute of Neuroanatomy, Faculty of Medicine, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany

    Birte Becker, Melek Demirbas, Sonja Johann, Adib Zendedel & Cordian Beyer

  2. Department of Anatomical Sciences, Faculty of Medicine, Giulan University of Medical Sciences, Rasht, Iran

    Adib Zendedel

  3. Department of Neurosurgery, Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany

    Hans Clusmann & Sonny Kian Hwie Tan

  4. Institute of Anatomy, Rostock University Medical Center, Gertrudenstr. 9, 18055, Rostock, Germany

    Stefan Jean-Pierre Haas & Andreas Wree

  5. Department of Anatomy II, Ludwig-Maximilians-University of Munich, Pettenkoferstr. 11, 80336, Munich, Germany

    Markus Kipp

Authors
  1. Birte Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melek Demirbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sonja Johann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adib Zendedel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cordian Beyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hans Clusmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stefan Jean-Pierre Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andreas Wree
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sonny Kian Hwie Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Markus Kipp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Birte Becker.

Ethics declarations

All procedures were conducted in accordance with local regulations and have been approved by the local Animal Commission (Iran and Rostock/Germany).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Becker, B., Demirbas, M., Johann, S. et al. Effect of Intrastriatal 6-OHDA Lesions on Extrastriatal Brain Structures in the Mouse. Mol Neurobiol 55, 4240–4252 (2018). https://doi.org/10.1007/s12035-017-0637-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-017-0637-9

Keywords

Search

Navigation